Agonist Treatment for Marijuana Dependence

大麻依赖激动剂治疗

• 批准号: 6801204
• 负责人: Frances Rudnick Levin
• 金额: $ 26.47万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6801204
• 关键词: behavior therapy; behavioral /social science research tag; cannabinoids; clinical trials; combination therapy; drug /alcohol abstinence; drug abuse chemotherapy; drug addiction; drug screening /evaluation; drug withdrawal; human subject; human therapy evaluation; interview; marijuana abuse; outcomes research; urinalysis

DESCRIPTION (provided by applicant): Epidemiologic studies have repeatedly shown that marijuana is the most commonly used illicit drug in the United States. Compared to other substances of abuse, the treatment of heavy and chronic marijuana use (dependence) has received comparatively little investigation. There is an increasing demand for marijuana treatment, but there are few controlled treatment trials that have targeted interventions for marijuana dependence. Our human laboratory studies have characterized substantial withdrawal symptoms associated with the abrupt cessation of marijuana. Laboratory studies have also found that orally administered tetrahydrocannabinol (THC) or dronabinol may have clinical utility in reducing these withdrawal effects in humans and may reduce the subjective effects of smoked marijuana. Further, an ongoing pilot study suggests that dronabinol may be administered safely in an outpatient setting. Incorporating this concept clinically, we propose a double-blind placebo-controlled 15-week trial testing the agonist dronabinol in conjunction with weekly Motivational Enhancement (MET) and Relapse Prevention (RPT) therapy. We hypothesize that reducing marijuana withdrawal symptoms will result in greater retention in treatment and lead to higher rates of abstinence in treatment seeking marijuana users. Following are the specific aims of this study: 1. To determine in marijuana-dependent individuals whether dronabinol is superior to placebo in promoting abstinence. 2. To determine in marijuana-dependent individuals whether dronabinol is superior to placebo in reducing withdrawal symptoms. 3. To determine whether the effects of dronabinol on withdrawal mediates abstinence in marijuana use / dependence (Mediational analysis). This study would be the first, double-blind, placebo-controlled study to assess the clinical utility of a cannabinoid agonist (dronabinol) for the treatment of marijuana dependence.

描述（由申请人提供）： 流行病学研究反复表明，大麻是美国最常用的非法药物。与其他滥用物质相比，对大麻使用（依赖）的治疗（依赖性）的研究相对较少。对大麻治疗的需求不断增加，但是很少有对照治疗试验针对大麻依赖的干预措施。我们的人类实验室研究表明，与大麻突然停止有关的大量戒断症状。实验室研究还发现，口服的四氢大麻酚（THC）或Dronabinol可能具有临床实用性，可以减少人类的戒断作用，并可能减少烟熏大麻的主观作用。此外，一项正在进行的试点研究表明，Dronabinol可以在门诊环境中安全地管理。在临床上结合了这一概念，我们提出了一项双盲安慰剂对照的15周试验，与每周的动机增强（MET）和预防复发（RPT）治疗结合使用激动剂Dronabinol。我们假设减少大麻戒断症状将导致治疗方面的保留率更高，并导致较高的戒酒率 大麻使用者。以下是这项研究的具体目的：1。确定大麻依赖性的个体，dronabinol是否优于安慰剂 促进禁欲。 2。确定大麻依赖的个体，在减少戒断症状方面，德罗替尔是否优于安慰剂。 3。确定Dronabinol对戒断的影响是否介导大麻使用 /依赖性（中介分析）。这项研究将是第一项评估大麻素激动剂（Dronabinol）治疗大麻依赖性的大麻素激动剂（Dronabinol）的临床实用性的研究。